AbbVie Inc. ABBV
Pharmaceutical Preparations · NYSE
Revenue
$54.32B
-6.4% YoY
Net income
$4.86B
-58.9% YoY
Total assets
$135.16B
+0.3% YoY
EPS
2.72
-59.0% YoY
Advertisement
Income Statement
| Period | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Revenues | — | — | $54.32B | — | — | — | $58.05B | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | $12.07B | — | — | — | $10.71B | — |
| SG&A Expense | $6.55B | $3.29B | $12.87B | $10.90B | $6.69B | $3.31B | $15.26B | $9.68B |
| Operating Income (Loss) | $8.63B | $3.73B | $12.76B | $10.63B | $6.80B | $2.80B | $18.12B | $9.56B |
| Interest Expense | $1.44B | $700.00M | $2.22B | $2.11B | $1.39B | $660.00M | $2.23B | $1.66B |
| Net Income (Loss) | $2.22B | $1.29B | $4.86B | $4.30B | $2.74B | $1.37B | $11.84B | $4.04B |
| EPS (Diluted) | 1.24 | 0.72 | 2.72 | 2.41 | 1.53 | 0.77 | 6.63 | 2.26 |
Balance Sheet
| Period | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $133.96B | $133.96B | $135.16B | $135.16B | $135.16B | $135.16B | $134.71B | $134.71B |
| Current Assets | $29.06B | $29.06B | $25.58B | $25.58B | $25.58B | $25.58B | $33.00B | $33.00B |
| Cash & Equivalents | $5.23B | $5.23B | $5.52B | $5.52B | $5.52B | $5.52B | $12.81B | $12.81B |
| Accounts Receivable | $12.59B | $12.59B | $10.92B | $10.92B | $10.92B | $10.92B | $11.15B | $11.15B |
| Inventory | $4.95B | $4.95B | $4.18B | $4.18B | $4.18B | $4.18B | $4.10B | $4.10B |
| PP&E (Net) | $5.63B | $5.63B | $5.13B | $5.13B | $5.13B | $5.13B | $4.99B | $4.99B |
| Goodwill | $35.64B | $35.64B | $32.29B | $34.96B | $34.96B | $34.96B | $32.16B | $32.29B |
| Current Liabilities | $43.29B | $43.29B | $38.75B | $38.75B | $38.75B | $38.75B | $37.84B | $37.84B |
| Accounts Payable | — | — | $2.94B | — | — | — | $3.69B | — |
| Long-Term Debt | — | — | $64.50B | — | — | — | $66.84B | — |
| Stockholders Equity | $-3.27B | $-3.27B | $3.33B | $3.33B | $3.33B | $3.33B | $10.36B | $10.36B |
Cash Flow Statement
| Period | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6.79B | $1.64B | $22.84B | $11.76B | $6.31B | $4.04B | $24.94B | $18.09B |
| Investing Cash Flow | $-1.92B | $-735.00M | $-2.01B | $-18.95B | $-10.69B | $-9.59B | $-623.00M | $-1.21B |
| Financing Cash Flow | $-3.97B | $-1.26B | $-17.22B | $1.65B | $4.72B | $10.82B | $-24.80B | $-12.77B |
| Stock Repurchases | $973.00M | $961.00M | $1.97B | $1.35B | $1.33B | $1.32B | $1.49B | $1.97B |
Similar companies
ABBOTT LABORATORIES
ABT
BRISTOL MYERS SQUIBB CO
BMY
JOHNSON & JOHNSON
JNJ
ELI LILLY & Co
LLY
Merck & Co., Inc.
MRK
PFIZER INC
PFE
REGENERON PHARMACEUTICALS, INC.
REGN
VERTEX PHARMACEUTICALS INC / MA
VRTX
Learn more
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Data is sourced from the U.S. SEC EDGAR public database. This site does not provide investment advice.